In summary, the present studies describe a novel mechanism by which ASA suppresses the in-vitro and in-vivo growth of highly aggressive B16F10 melanoma tumors via SOX2-dependent-PAF-R independent signaling pathway. Here, SOX2 is linked to melanoma.